Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1478184 | 1.00 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1478166 | 1.00 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2225858 | 0.95 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL239130 | 0.95 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL240483 | 0.95 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL5069216 | 0.88 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1398934 | 0.88 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL29755212 | 0.88 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1118578 | 0.88 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL21334251 | 0.88 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-11702444-B2 | Method for preparing natural bioactive peptide Tubulysin U | SHENZHEN INSTITUTE OF GERIATRICS (CN) | 2023-07-18 | — | — | US | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20200392107-A1 | CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2020-12-17 | — | — | US | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| CN-101001840-A | Therapeutic compounds: pyridines as skeletons | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | HSD17B10 2988/4885SMN1; SMN2 1107/4885NPC1 2178/4885 |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | HSD17B10 2403/4885SMN1; SMN2 3758/4885NPC1 1810/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | HSD17B10 2988/4885SMN1; SMN2 1107/4885NPC1 2178/4885 |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | TYMP, TYMS, POLA1 | HSD17B10 2403/4885SMN1; SMN2 3759/4885NPC1 1816/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | HSD17B10 2427/4885SMN1; SMN2 4220/4885NPC1 1597/4885 |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | HSD17B10 276/4885SMN1; SMN2 1510/4885NPC1 113/4885 |
| US-20200392107-A1 | CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF | NPR3, SLC10A1, CNR2 | HSD17B10 836/4885SMN1; SMN2 3077/4885NPC1 609/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | HSD17B10 3051/4885SMN1; SMN2 174/4885NPC1 2895/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | HSD17B10 2988/4885SMN1; SMN2 1107/4885NPC1 2178/4885 |
| US-11702444-B2 | Method for preparing natural bioactive peptide Tubulysin U | VIP, MLN, HNRNPU | HSD17B10 4455/4885SMN1; SMN2 3124/4885NPC1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.